Endothelial dysfunction in diabetes mellitus

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 54, Issue 1, 1996, Pages 45-51

  Chakir, M ^a   Plante, G E ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; EVANS BLUE; MINALRESTAT; NITRIC OXIDE; SORBINIL; STREPTOZOCIN;

ANIMAL MODEL; BRONCHUS; CAPILLARY PERMEABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DUODENUM; ENDOTHELIUM; EXTRAVASATION; FEMALE; HEART; KIDNEY; LUNG; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SKIN;

ANIMALIA; BRONCHUS;

EID: 0029992040     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90080-0     Document Type: Conference Paper

References (48)

1. Christrieb A R. Diabetes and hypertensive vascular disease. Mechanism and treatment. Am J Cardiol 1973; 32: 592-606.
2. Jensen T, Borch-Johnson K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987; 30: 144-148.
3. Lorenzi M, Cagliero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus. Diabetes 1991; 40: 653-659.
4. Porta M, La Selva M, Molinatti P, Molinatti G M. Endothelial cell function in diabetic microangiopathy. Diabetologia 1987; 30: 601-609.
5. Dvornik D, Simard-Duquesne N, Krami N et al. Polyol accumulation in galactosemic and diabetic rats: control by AR inhibitor. Science 1973; 182: 1146-1147.
6. Gabbay K H. Role of sorbitol pathway in neuropathology. Adv Metab Disord 1973; 2: 417-424.
7. Clements R S Jr, Morrison A D, Winegrad A I. Polyol pathway in aorta: regulation by hormones. Science 1969; 166: 1007-1008.
8. Beyer-Mears A, Ku L, Cohen M P. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil. Diabetes 1984; 33: 604-607.
9. Ross R. The pathogenesis of atherosclerosis. An update. N Engl J Med 1986; 314: 488-500.
10. Sirois M G, Plante G E, Braquet P, Sirois P. Role of eicosanoids in PAF-induced increases of vascular permeability in rat airways. Br J Pharmacol 1990; 101: 896-900.
11. Lehoux S, Plante G E, Sirois M G, D'Orléans-Juste P. Phosphoramidon blocks big-endothelin-1 but not endothelin-1 enhancement of vascular permeability in the rat. Br J Pharmacol 1992; 107: 996-1000.
12. Aukland K, Nicolaysen ?. Interstitial fluid volume: local regulatory mechanisms. Physiol Rev 1981; 61: 556-643.
13. Aukland K, Reed R K. Interstitial lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 1993; 73: 1-78.
14. Palmer R M J, Ferrige A G, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
15. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
16. D'Orléans-Juste P, Claing A, Warner T D, Yano M, Telemaque S. Characterisation of receptors for endothelins in the perfused arterial and venous mesenteric vasculatures of the rat. Br J Pharmacol 1993; 110: 687-692.
17. Warner T D. Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparaison of their vasoconstrictor and vasodilator responses to agonists. Br J Pharmacol 1990; 99: 427-433.
18. Takahashi K, Ghatei M A, Lam H C, O'Halloran D J, Bloom S R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990; 33: 306-310.
19. Jancar S, Degiacobbi G, Mariano M, Sirois P, Braquet P. Involvement of platelet-activating factor in acute immunecomplex-induced pancreatitis. In: Braquet P, ed. New trends in lipid mediators research. Basel: Karger, 1988: 194-198.
20. Rogers D F, Boschetto P, Barnes P J. Plasma exudation correlation between Evans blue dye and radiolabeled albumin in guinea pig airways in vivo. J Pharmacol Meth 1989; 21: 309-315.
21. Patterson C E, Rhoades R A, Garcia J G. Evans blue dye as a marker of albumin clearance in cultured endothelial monolayer and isolated lung. J Appl Physiol 1992; 72: 865-873.
22. Wiig H, DeCarlo M, Sibley L, Renkin E M. Interstitial exclusion of albumin in rat tissues measured by a continuous infusion method. Am J Physiol 1992; 263: H1222.
23. Manery J. Water and electrolyte metabolism. Physiol Rev 1954; 34: 334-352.
24. 2, but not noradrenaline, of aortae from rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol 1991; 104: 928-932.
25. Wysolmerski R B, Lagunoff D. Regulation of permeabilized endothelial cell retraction by myosin phosphorylation. Am J Physiol 1991; 261: C32-40.
26. Corbett J A, Tilton R G, Chang K et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 41: 552-556.
27. Filep J G, Foldes-Filep E, Sirois P. Nitric oxide modulates vascular permeability in the rat coronary circulation. Br J Pharmacol 1993; 108: 323-326.
28. Bucala R, Tracey K J, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-438.
29. Filep J G, Sirois M G, Foldes-Filep E et al. Enhancement by endothelin-1 of microvascular permeability via the activation of ETA receptors. Br J Pharmacol 1993; 109: 880-886.
30. Cavero P G, Miller W L, Heublein D M, Margulies K B, Brunett J C. Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol 1990; 259: F312-F317.
31. Margulies K B, Hildbrand F L, Lerman A, Perrella M A, Brunett J C. Increased endothelin in experimental heart failure. Circulation 1990; 82: 2226-2230.
32. Widimsky J Jr, Horky K, Dvorakova J. Plasma endothelin 1,2 levels in mild and severe hypertension. J Hypertens 1991; 9 (Suppl): S194-S195.
33. Lerman A, Edwards B S, Hallet J W, Heublein D M, Sandberg S M, Brunett J C Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
34. Collier A, Leach J P, Mclellan A, Jardine A, Morton J J, Small M. Plasma endothelin-like immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care 1992; 1038-1040.
35. Haak T, Jungmann E, Felber A, Hillmann U, Usadel K H. Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens 1992; 5: 161-166.
36. Yamauchi T, Ohnaka K, Takayanagi R, Umeda F, Nawata H. Enhanced secretion of endothelin 1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 1990; 267: 16-18.
37. Beyer-Mears A, Ku L, Cohen M P. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil. Diabetes 1984; 33: 604-607.
38. Williamson J R, Chang K, Rowold E et al. Diabetes-induced increases in vascular permeability and changes in granulation tissue levels of sorbitol, myo-inositol, chiro-inositol and scyllo-inositol are prevented by sorbinil. Metabolism 1986; 35: 41-45.
39. Peterson M J, Sarges R, Aldinger C E, MacDonald D P: CP-54,643, a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats. Metabolism. 1979; 8: 456-461.
40. Beyer-Mears A, Cruz E, Eldelist T, Varagiannis E. Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor. Pharmacology 1986; 32: 52-60.
41. Gillon K R W, Hawthorne J N, Tomlinson D R. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition. Diabetologia 1983; 25: 365-371.
42. Sima A A F, Bril V, Nathaniel V et al. Regeneration and repair of myelinated fibers in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988; 319: 548-555.
43. Bank N, Coco M, Aynedjian H S. Galactose feeding causes glomerular hyperperfusion: Prevention by aldose reductase inhibition. Am J Physiol 1989; 256: F994-F999.
44. + ATP-ase activity. J Clin Invest 1986; 77: 503-513.
45. Greene D A, Lattimer S A, Sima A A F. Sorbitol, phosphoinositides and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599-606.
46. Brismar T, Sima A A F, Greene D A. Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 1987; 21: 504-507.
47. MacGregor L C, Matschinsky F M. Treatment with an aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats. J Clin Invest 1985; 76: 887-889.
48. Tilton R G, Chang K, Hasan K S et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42: 221-232.